Compare AJANTA PHARMA with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs INDOCO REMEDIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA INDOCO REMEDIES AJANTA PHARMA/
INDOCO REMEDIES
 
P/E (TTM) x 22.3 22.2 100.7% View Chart
P/BV x 5.3 4.5 119.0% View Chart
Dividend Yield % 0.8 0.4 190.0%  

Financials

 AJANTA PHARMA   INDOCO REMEDIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-21
INDOCO REMEDIES
Mar-21
AJANTA PHARMA/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,883336 561.2%   
Low Rs1,258190 662.1%   
Sales per share (Unadj.) Rs334.0134.7 247.9%  
Earnings per share (Unadj.) Rs75.610.1 748.4%  
Cash flow per share (Unadj.) Rs89.018.0 493.4%  
Dividends per share (Unadj.) Rs9.501.50 633.3%  
Avg Dividend yield %0.60.6 106.0%  
Book value per share (Unadj.) Rs346.183.4 414.8%  
Shares outstanding (eoy) m86.5392.15 93.9%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x4.72.0 241.1%   
Avg P/E ratio x20.826.0 79.9%  
P/CF ratio (eoy) x17.714.6 121.1%  
Price / Book Value ratio x4.53.1 144.1%  
Dividend payout %12.614.9 84.6%   
Avg Mkt Cap Rs m135,89824,215 561.2%   
No. of employees `000NANA-   
Total wages/salary Rs m5,4832,740 200.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m28,89712,415 232.8%  
Other income Rs m26091 286.8%   
Total revenues Rs m29,15712,506 233.1%   
Gross profit Rs m9,9862,183 457.4%  
Depreciation Rs m1,161731 158.8%   
Interest Rs m83223 37.1%   
Profit before tax Rs m9,0021,320 682.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,463390 632.3%   
Profit after tax Rs m6,539930 702.7%  
Gross profit margin %34.617.6 196.5%  
Effective tax rate %27.429.5 92.7%   
Net profit margin %22.67.5 301.9%  
BALANCE SHEET DATA
Current assets Rs m22,1786,225 356.3%   
Current liabilities Rs m8,3884,069 206.1%   
Net working cap to sales %47.717.4 274.8%  
Current ratio x2.61.5 172.8%  
Inventory Days Days5322 243.7%  
Debtors Days Days9687 1.4%  
Net fixed assets Rs m18,9127,117 265.7%   
Share capital Rs m174184 94.4%   
"Free" reserves Rs m29,7777,506 396.7%   
Net worth Rs m29,9517,690 389.5%   
Long term debt Rs m16969 1.7%   
Total assets Rs m41,09013,343 308.0%  
Interest coverage x109.86.9 1,585.3%   
Debt to equity ratio x00.1 0.4%  
Sales to assets ratio x0.70.9 75.6%   
Return on assets %16.18.6 186.5%  
Return on equity %21.812.1 180.4%  
Return on capital %30.317.8 170.2%  
Exports to sales %043.7 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA5,426 0.0%   
Imports (cif) Rs mNA1,270 0.0%   
Fx inflow Rs m18,0975,426 333.5%   
Fx outflow Rs m2,3151,270 182.3%   
Net fx Rs m15,7824,157 379.7%   
CASH FLOW
From Operations Rs m5,763822 700.9%  
From Investments Rs m-2,824-667 423.4%  
From Financial Activity Rs m-3,183-299 1,065.5%  
Net Cashflow Rs m-244-143 169.9%  

Share Holding

Indian Promoters % 70.5 58.7 120.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 21.4 19.4 110.1%  
FIIs % 8.6 1.2 751.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.5 41.3 71.5%  
Shareholders   60,759 37,863 160.5%  
Pledged promoter(s) holding % 16.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    

Yellow Ad

Advertisement

How to Find One Stock with Crorepati Potential?

There are three critical characteristics that differentiate a common stock from a potential 'crorepati' stock.

And we are going to reveal them during our 'One Stock Crorepati' MEGA summit on 30th June.

If you are interested in finding a potential 'crorepati' stock, don't miss this.

At this MEGA Summit we will reveal details of what we call a 'crorepati' stock...

You just cannot afford to miss this summit for anything.

Learn more



Today's Market

Sensex, Nifty Rebound from Day's Low to End Flat; IT & Auto Stocks Witness Buying(Closing)

Indian share markets witnessed a volatile trading session today as crude oil prices rebounded following last week's rout.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 28, 2022 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS